Michel Ducreux

Board member

Education: MD, PhD, Professor of Medical Oncology.

Background: Head of the digestive oncology unit and the digestive cancer group at Gustave Roussy (Cancer Centre in Paris, France) since 1997. Author of more than 540 articles published in indexed journals. Main research topics: management of metastatic colorectal cancer, metastatic pancreatic carcinoma, bile carcinoma, hepatocellular carcinoma and the treatment of neuroendocrine tumors. Various leadership roles in ESMO and EORTC related to gastrointestinal oncology. Participation in more than 300 clinical trials during the last 25 years and Principal Investigator of more than 80 clinical trials during the last 15 years.

Other ongoing assignments: Head of GI oncology Unit, Department of Medical Oncology, Inserm U1279, Team “Endocytosis, Cytoskeleton and Cell Migration” and member of the scientific advisory boards of RenovoRx and Abcely.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants
No shares or warrants.